Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13708739 | 1.00 | HTT (0.45) | HTTSMN1; SMN2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL13708740 | 1.00 | HTT (0.45) | HTTSMN1; SMN2CYP3A4CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL28481257 | 0.98 | HTT (0.44) | HTTSMN1; SMN2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL25589521 | 0.77 | SMN1; SMN2 (0.46) | HTTSMN1; SMN2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL25590015 | 0.77 | SMN1; SMN2 (0.49) | HTTSMN1; SMN2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL22520077 | 0.76 | — | — | |
| SCHEMBL25142177 | 0.75 | ALDH1A1 (0.46) | HTTSMN1; SMN2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL19982848 | 0.75 | HTT (0.44) | HTTSMN1; SMN2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL9019 | 0.70 | TP53 (0.45) | HTTSMN1; SMN2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL23343732 | 0.70 | TP53 (0.51) | HTTSMN1; SMN2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4370207-B1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20240368137-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2024-11-07 | — | — | US | disclosed |
| US-12012398-B2 | Bicyclic compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| EP-4370207-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | Nido Biosciences, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| CN-116234552-A | Dual modulators of mGluR5 and 5-HT2A receptors and uses thereof | (株)倍宝尊 | 2023-06-06 | — | — | CN | disclosed |
| US-20230131260-A1 | SUBSTITUTED THIOPHENYL URACILS, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | SYNGENTA CROP PROTECTION AG (CH) | 2023-04-27 | — | — | US | disclosed |
| US-20230039586-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20230039586-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2023287704-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023287704-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-20120232076-A1 | QUINOLIZIDINONE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-09-13 | — | — | US | disclosed |
| US-20120232076-A1 | QUINOLIZIDINONE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-09-13 | — | — | US | disclosed |
| CN-102498107-A | Heteroaryl compounds as kinase inhibitors | NOVARTIS AG | 2012-06-13 | — | — | CN | disclosed |
| CN-102482265-A | Pyrazinylpyridines useful for the treatment of proliferative diseases | NOVARTIS AG | 2012-05-30 | — | — | CN | disclosed |
| CN-102471310-A | Bipyridines useful for the treatment of proliferative diseases | NOVARTIS AG | 2012-05-23 | — | — | CN | disclosed |
| US-20110160206-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-06-30 | — | — | US | disclosed |
| WO-2011062853-A1 | QUINOLIZIDINONE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2010027097-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-11 | — | — | WO | disclosed |
| US-7582651-B2 | Pyrrolopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-01 | — | — | US | disclosed |
| US-7582651-B2 | Pyrrolopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039586-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | HTT 845/4885SMN1; SMN2 1055/4885CYP3A4 2305/4885 |
| US-20240368137-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | HTT 845/4885SMN1; SMN2 1055/4885CYP3A4 2305/4885 |
| US-20120232076-A1 | QUINOLIZIDINONE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CHRM2, CHRM4 | HTT 584/4885SMN1; SMN2 2003/4885CYP3A4 423/4885 |
| US-12012398-B2 | Bicyclic compounds as androgen receptor modulators | AR, FSHR, NCOA3 | HTT 707/4885SMN1; SMN2 1205/4885CYP3A4 2152/4885 |
| US-20110160206-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PDE10A, PDE12, PDE9A | HTT 4547/4885SMN1; SMN2 2888/4885CYP3A4 1089/4885 |
| US-20230131260-A1 | SUBSTITUTED THIOPHENYL URACILS, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | UNG, TYMP, TYMS | HTT 1704/4885SMN1; SMN2 4823/4885CYP3A4 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.